Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
20-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
20-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
19 May 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/casi-pharmaceuticals-provides-business-and-clinical-update-1028949
12 May 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/casi-pharmaceuticals-enters-into-definitive-agreement-for-the-divesti-1026311
16 Nov 2023
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-urges-acrotech-speed-up-study-cancer-drugs-2023-11-16/
24 Nov 2022
// INDIANPHARMAPOST
https://www.indianpharmapost.com/news/evive-enters-license-agreement-with-acrotech-biopharma-to-commercialize-ryzneuta-in-us-13335
24 Sep 2021
// Z. Brennan ENDPTS
https://endpts.com/fdas-cancer-drug-advisors-will-review-2-more-dangling-accelerated-approvals-for-multiple-myeloma-leukemia/
26 Apr 2021
// BUSINESSWIRE
https://www.businesswire.com/news/home/20210426005126/en/Acrotech-Biopharma-Announces-the-Publication-of-Data-From-a-Phase-1-Study-of-BELEODAQ%C2%AE-belinostat-Combined-With-Standard-CHOP-Bel-CHOP-in-Patients-With-Previously-Untreated-Peripheral-T-cell-Lymphoma
ABOUT THIS PAGE